de Charles Schwab BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 23.5 M | Comprar |
2,353,291
+2,886
| +0.1% | +USD 26.1 k | ﹤0.01% | 1736 |
|
|
2026
Q1 | USD 22.4 M | Comprar |
2,350,405
+345,466
| +17% | +USD 2.68 M | ﹤0.01% | 1682 |
|
|
2025
Q4 | USD 15.6 M | Comprar |
2,004,939
+10,535
| +0.5% | +USD 76.2 k | ﹤0.01% | 1902 |
|
|
2025
Q3 | USD 15.1 M | Comprar |
1,994,404
+24,529
| +1% | +USD 204 k | ﹤0.01% | 1898 |
|
|
2025
Q2 | USD 17.7 M | Comprar |
1,969,875
+47,837
| +2% | +USD 445 k | ﹤0.01% | 1740 |
|
|
2025
Q1 | USD 14.4 M | Vender |
1,922,038
-57,954
| -3% | -USD 467 k | ﹤0.01% | 1789 |
|
|
2024
Q4 | USD 14.9 M | Comprar |
1,979,992
+91,998
| +5% | +USD 698 k | ﹤0.01% | 1840 |
|
|
2024
Q3 | USD 14.3 M | Comprar |
1,887,994
+102,860
| +6% | +USD 782 k | ﹤0.01% | 1865 |
|
|
2024
Q2 | USD 11 M | Comprar |
1,785,134
+53,331
| +3% | +USD 294 k | ﹤0.01% | 1998 |
|
|
2024
Q1 | USD 8.8 M | Comprar |
1,731,803
+137,367
| +9% | +USD 773 k | ﹤0.01% | 2049 |
|
|
2023
Q4 | USD 9.6 M | Comprar |
1,594,436
+133,629
| +9% | +USD 774 k | ﹤0.01% | 2008 |
|
|
2023
Q3 | USD 10.3 M | Comprar |
1,460,807
+19,402
| +1% | +USD 139 k | ﹤0.01% | 1891 |
|
|
2023
Q2 | USD 10.1 M | Comprar |
1,441,405
+18,285
| +1% | +USD 147 k | ﹤0.01% | 1904 |
|
|
2023
Q1 | USD 11.9 M | Comprar |
1,423,120
+2,733
| +0.2% | +USD 26.3 k | ﹤0.01% | 1790 |
|
|
2022
Q4 | USD 16.3 M | Comprar |
1,420,387
+34,239
| +2% | +USD 427 k | 0.01% | 1577 |
|
|
2022
Q3 | USD 17.5 M | Comprar |
1,386,148
+29,145
| +2% | +USD 375 k | 0.01% | 1471 |
|
|
2022
Q2 | USD 14.4 M | Comprar |
1,357,003
+10,162
| +0.8% | +USD 105 k | 0.01% | 1625 |
|
|
2022
Q1 | USD 21.9 M | Comprar |
1,346,841
+72,026
| +6% | +USD 1.16 M | 0.01% | 1475 |
|
|
2021
Q4 | USD 17.7 M | Comprar |
1,274,815
+30,649
| +2% | +USD 406 k | 0.01% | 1680 |
|
|
2021
Q3 | USD 17.9 M | Comprar |
1,244,166
+17,055
| +1% | +USD 269 k | 0.01% | 1671 |
|
|
2021
Q2 | USD 19.4 M | Comprar |
1,227,111
+20,145
| +2% | +USD 274 k | 0.01% | 1611 |
|
|
2021
Q1 | USD 12.3 M | Comprar |
1,206,966
+38,275
| +3% | +USD 395 k | ﹤0.01% | 1838 |
|
|
2020
Q4 | USD 8.71 M | Vender |
1,168,691
-1,355
| -0.1% | -USD 6.98 k | ﹤0.01% | 1942 |
|
|
2020
Q3 | USD 4.02 M | Comprar |
1,170,046
+242,102
| +26% | +USD 1.04 M | ﹤0.01% | 2181 |
|
|
2020
Q2 | USD 4.42 M | Comprar |
927,944
+68,937
| +8% | +USD 275 k | ﹤0.01% | 2084 |
|
|
2020
Q1 | USD 1.72 M | Comprar |
859,007
+23,758
| +3% | +USD 65.4 k | ﹤0.01% | 2325 |
|
|
2019
Q4 | USD 2.88 M | Comprar |
835,249
+259,443
| +45% | +USD 653 k | ﹤0.01% | 2298 |
|
|
2019
Q3 | USD 1.65 M | Vender |
575,806
-76,927
| -12% | -USD 239 k | ﹤0.01% | 2447 |
|
|
2019
Q2 | USD 2.47 M | Vender |
652,733
-126,632
| -16% | -USD 762 k | ﹤0.01% | 2300 |
|
|
2019
Q1 | USD 6.34 M | Comprar |
779,365
+181,543
| +30% | +USD 1.55 M | ﹤0.01% | 1861 |
|
|
2018
Q4 | USD 4.82 M | Vender |
597,822
-18,081
| -3% | -USD 141 k | ﹤0.01% | 1921 |
|
|
2018
Q3 | USD 4.7 M | Comprar |
615,903
+96,843
| +19% | +USD 650 k | ﹤0.01% | 2076 |
|
|
2018
Q2 | USD 2.98 M | Comprar |
519,060
+28,084
| +6% | +USD 155 k | ﹤0.01% | 2248 |
|
|
2018
Q1 | USD 2.34 M | Vender |
490,976
-5,816
| -1% | -USD 29.9 k | ﹤0.01% | 2270 |
|
|
2017
Q4 | USD 2.44 M | Comprar |
496,792
+176,714
| +55% | +USD 856 k | ﹤0.01% | 2236 |
|
|
2017
Q3 | USD 1.68 M | Comprar |
320,078
+12,267
| +4% | +USD 62.8 k | ﹤0.01% | 2348 |
|
|
2017
Q2 | USD 1.71 M | Vender |
307,811
-25,562
| -8% | -USD 156 k | ﹤0.01% | 2271 |
|
|
2017
Q1 | USD 2.8 M | Comprar |
333,373
+62,792
| +23% | +USD 437 k | ﹤0.01% | 2059 |
|
|
2016
Q4 | USD 1.71 M | Comprar |
270,581
+13,398
| +5% | +USD 69.7 k | ﹤0.01% | 2239 |
|
|
2016
Q3 | USD 1.14 M | Comprar |
257,183
+11,454
| +5% | +USD 45.8 k | ﹤0.01% | 2375 |
|
|
2016
Q2 | USD 698 k | Comprar |
245,729
+3,528
| +1% | +USD 11 k | ﹤0.01% | 2467 |
|
|
2016
Q1 | USD 686 k | Vender |
242,201
-23,769
| -9% | -USD 105 k | ﹤0.01% | 2464 |
|
|
2015
Q4 | USD 2.74 M | Comprar |
265,970
+20,210
| +8% | +USD 201 k | ﹤0.01% | 1905 |
|
|
2015
Q3 | USD 2.8 M | Comprar |
245,760
+35,885
| +17% | +USD 479 k | ﹤0.01% | 1857 |
|
|
2015
Q2 | USD 3.13 M | Comprar |
209,875
+5,769
| +3% | +USD 65.6 k | ﹤0.01% | 1848 |
|
|
2015
Q1 | USD 1.84 M | Vender |
204,106
-274,277
| -57% | -USD 2.84 M | ﹤0.01% | 2095 |
|
|
2014
Q4 | USD 5.82 M | Comprar |
478,383
+28,362
| +6% | +USD 313 k | 0.01% | 1333 |
|
|
2014
Q3 | USD 4.4 M | Comprar |
450,021
+200,061
| +80% | +USD 2.45 M | 0.01% | 1473 |
|
|
2014
Q2 | USD 3.19 M | Comprar |
249,960
+226,060
| +946% | +USD 2.2 M | 0.01% | 1708 |
|
|
2014
Q1 | USD 253 k | Mantener |
23,900
| – | – | ﹤0.01% | 2872 |
|
|
2013
Q4 | USD 182 k | Mantener |
23,900
| – | – | ﹤0.01% | 2973 |
|
|
2013
Q3 | USD 182 k | Mantener |
23,900
| – | – | ﹤0.01% | 2949 |
|
|
2013
Q2 | USD 39 k | Comprar |
+23,900
| Nuevas | +USD 41.2 k | ﹤0.01% | 3038 |
|
Otros fondos que tienen BCRX en su cartera
Posición de Charles Schwab en BCRX: resumen de T2 2026
Charles Schwab aumentó su participación en BioCryst Pharmaceuticals (BCRX) en 0.12% durante T2 2026, al comprar aproximadamente USD 26.1 k y elevar la posición a 2,353,291 acciones con un valor de USD 23.5 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1736.
Charles Schwab reportó por primera vez una posición en BCRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, Charles Schwab tenía 2,353,291 acciones de BioCryst Pharmaceuticals con un valor de USD 23.5 M.
- Charles Schwab compró 2,886 acciones de BioCryst Pharmaceuticals en T2 2026, por un monto estimado de USD 26.1 k.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de Charles Schwab en T2 2026 y fue su posición número 1736.
- Charles Schwab reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de Charles Schwab correspondiente a T2 2026, presentado el 14 ago 2026.